Entry
Name
Hepatocellular carcinoma; Liver cancer
Description
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. It has been shown that, after HBV/HCV infection and alcohol or aflatoxin B1 exposure, genetic and epigenetic changes occur. The recurrent mutated genes were found to be highly enriched in multiple key driver signaling processes, including telomere maintenance, TP53, cell cycle regulation, the Wnt/beta-catenin pathway (CTNNB1 and AXIN1), the phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Recent studies using whole-exome sequencing have revealed recurrent mutations in new driver genes involved in the chromatin remodelling (ARID1A and ARID2) and the oxidative stress (NFE2L2) pathways.
Category
Cancer
Brite
Human diseases [BR:br08402]
Cancers
Cancers of the digestive system
H00048 Hepatocellular carcinoma
Human diseases in ICD-11 classification [BR:br08403]
02 Neoplasms
Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
Malignant neoplasms of digestive organs
2C12 Malignant neoplasms of liver or intrahepatic bile ducts
H00048 Hepatocellular carcinoma
Tumor markers [br08442.html]
H00048
Cancer-associated carbohydrates [br08441.html]
H00048
BRITE hierarchy
Pathway
hsa05225 Hepatocellular carcinoma
Related pathway
Network
nt06110 MAPK signaling (viruses and bacteria) nt06114 PI3K signaling (viruses) nt06119 JAK-STAT signaling (viruses) nt06121 TLR signaling (viruses and bacteria) nt06122 IFN signaling (viruses) nt06123 TNF signaling (viruses and bacteria) nt06124 Chemokine signaling (viruses) nt06130 Cell cycle (viruses) nt06131 Apoptosis (viruses and bacteria) nt06133 RLR signaling (viruses) nt06137 OAS/RNase L pathway (viruses) nt06140 Transcription (viruses) nt06162 Hepatitis B virus (HBV) nt06163 Hepatitis C virus (HCV) nt06263 Hepatocellular carcinoma nt06505 WNT signaling nt06507 TGFB signaling
Gene
TGFA (overexpression) [HSA:7039] [KO:K08774]
IGF2 (overexpression) [HSA:3481] [KO:K13769]
IGF1R (overexpression) [HSA:3480] [KO:K05087]
TERT (overexpression) [HSA:7015] [KO:K11126]
FZD7 (overexpression) [HSA:8324] [KO:K02432]
HGF (overexpression) [HSA:3082] [KO:K05460]
MET (mutation, overexpression) [HSA:4233] [KO:K05099]
MYC (amplification) [HSA:4609] [KO:K04377]
RB1 (loss) [HSA:5925] [KO:K06618]
CDKN2A (deletion) [HSA:1029] [KO:K06621]
TGFBR2 (reduced expression) [HSA:7048] [KO:K04388]
TP53 [HSA:7157] [KO:K04451]
PTEN [HSA:5728] [KO:K01110]
CTNNB1 [HSA:1499] [KO:K02105]
AXIN1 [HSA:8312] [KO:K02157]
KEAP1 [HSA:9817] [KO:K10456]
NFE2L2 [HSA:4780] [KO:K05638]
PIK3CA [HSA:5290] [KO:K00922]
ARID1A [HSA:8289] [KO:K11653]
ARID2 [HSA:196528] [KO:K11765]
CASP8 [HSA:841] [KO:K04398]
IGF2R [HSA:3482] [KO:K06564]
Pathogen
Hepatitis B virus [GN:T40004] Hepatitis C virus [GN:T40066]
Drug
Sorafenib tosylate [DR:D06272]
Regorafenib hydrate [DR:D10137]
Cabozantinib s-malate [DR:D10095]
Lenvatinib mesylate [DR:D09920]
Nivolumab [DR:D10316]
Pembrolizumab [DR:D10574]
Atezolizumab [DR:D10773]
Bevacizumab [DR:D06409]
Ramucirumab [DR:D09371]
Ipilimumab [DR:D04603]
Tremelimumab [DR:D06657]
Other DBs
Reference
PMID:21829020
Authors
Kudo M
Title
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Journal
Dig Dis 29:289-302 (2011) DOI:10.1159/000327562
Reference
PMID:27895396
Authors
Niu ZS, Niu XJ, Wang WH
Title
Genetic alterations in hepatocellular carcinoma: An update.
Journal
World J Gastroenterol 22:9069-9095 (2016) DOI:10.3748/wjg.v22.i41.9069
Reference
PMID:16799620
Authors
Breuhahn K, Longerich T, Schirmacher P
Title
Dysregulation of growth factor signaling in human hepatocellular carcinoma.
Journal
Oncogene 25:3787-800 (2006) DOI:10.1038/sj.onc.1209556
Reference
PMID:20639898
Authors
Whittaker S, Marais R, Zhu AX
Title
The role of signaling pathways in the development and treatment of hepatocellular carcinoma.
Journal
Oncogene 29:4989-5005 (2010) DOI:10.1038/onc.2010.236
Reference
PMID:19387255
Authors
Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM
Title
Pathogenesis of hepatocellular carcinoma and molecular therapies.
Journal
Curr Opin Gastroenterol 25:186-94 (2009) DOI:10.1097/MOG.0b013e32832962a1
Reference
PMID:15085488
Authors
Suriawinata A, Xu R
Title
An update on the molecular genetics of hepatocellular carcinoma.
Journal
Semin Liver Dis 24:77-88 (2004) DOI:10.1055/s-2004-823102
Reference
PMID:22922871
Authors
Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF, Fei QL, Chen H, Cai B, Zhou B, Xiao HS, Qin LX, Han ZG
Title
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma.
Journal
Nat Genet 44:1117-21 (2012) DOI:10.1038/ng.2391
Reference
PMID:17295177
Authors
Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM.
Title
Genomics and signaling pathways in hepatocellular carcinoma.
Journal
Semin Liver Dis 27:55-76 (2007) DOI:10.1055/s-2006-960171
Reference
PMID:11935086
Authors
Rocken C, Carl-McGrath S.
Title
Pathology and pathogenesis of hepatocellular carcinoma.
Journal
Dig Dis 19:269-78 (2001) DOI:10.1159/000050693
Reference
PMID:12149612
Authors
Thorgeirsson SS, Grisham JW.
Title
Molecular pathogenesis of human hepatocellular carcinoma.
Journal
Nat Genet 31:339-46 (2002) DOI:10.1038/ng0802-339
Reference
PMID:21251164 (KEAP1, NFE2L2)
Authors
Taguchi K, Motohashi H, Yamamoto M
Title
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution.
Journal
Genes Cells 16:123-40 (2011) DOI:10.1111/j.1365-2443.2010.01473.x
Reference
PMID:22348534 (KEAP1, NFE2L2)
Authors
Yoo NJ, Kim HR, Kim YR, An CH, Lee SH
Title
Somatic mutations of the KEAP1 gene in common solid cancers.
Journal
Histopathology 60:943-52 (2012) DOI:10.1111/j.1365-2559.2012.04178.x
Reference
PMID:22561517 (CTNNB1, AXIN1, ARID1A, ARID2)
Authors
Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, Calvo F, Zucman-Rossi J
Title
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
Journal
Nat Genet 44:694-8 (2012) DOI:10.1038/ng.2256
Reference
PMID:27508192 (MET)
Authors
Granito A, Guidetti E, Gramantieri L
Title
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma.
Journal
J Hepatocell Carcinoma 2:29-38 (2015) DOI:10.2147/JHC.S77038
Reference
PMID:15608678 (PIK3CA)
Authors
Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH
Title
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Journal
Oncogene 24:1477-80 (2005) DOI:10.1038/sj.onc.1208304
Reference
PMID:23887712 (TERT)
Authors
Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J
Title
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Journal
Nat Commun 4:2218 (2013) DOI:10.1038/ncomms3218
Reference
PMID:15531912 (CASP8)
Authors
Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH
Title
Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas.
Journal
Oncogene 24:141-7 (2005) DOI:10.1038/sj.onc.1208244
Reference
PMID:7493029 (IGF2R)
Authors
De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL
Title
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.
Journal
Nat Genet 11:447-9 (1995) DOI:10.1038/ng1295-447